Urinary transglutaminase 2 as a potent biomarker to predict interstitial fibrosis and tubular atrophy of kidney allograft during early posttransplant period in deceased donor kidney transplantation
Annals of Surgical Treatment and Research
;
: 27-35, 2019.
Article
in English
| WPRIM
| ID: wpr-762680
ABSTRACT
PURPOSE:
Transglutaminase type 2 (TG2) is an extracellular matrix crosslinking enzyme with a pivotal role in kidney fibrosis. We tested whether quantification of urinary TG2 may represent a noninvasive method to estimate the severity of kidney allograft fibrosis.METHODS:
We prospectively collected urine specimens from 18 deceased donor kidney transplant recipients at 1-day, 7-day, 1-month, 3-month, and 6-month posttransplant. In addition, kidney allograft tissue specimens at 0-day and 6-month posttransplant were sampled to analyze the correlation of urinary TG2 and kidney allograft fibrosis.RESULTS:
Thirteen recipients had increased interstitial fibrosis and tubular atrophy (IFTA) scores at the 6-month protocol biopsy (IFTA group). The mean level of urinary TG2 in the IFTA group was higher compared to that of 5 other recipients without IFTA (no IFTA group). Conversely, the mean level of urinary syndecan-4 in the IFTA group was lower than levels in patients without IFTA. In the IFTA group, double immunofluorescent staining revealed that TG2 intensity was significantly upregulated and colocalizations of TG2/heparin sulfate proteoglycan and nuclear syndecan-4 were prominent, usually around tubular structures.CONCLUSION:
Urinary TG2 in early posttransplant periods is a potent biomarker for kidney allograft inflammation or fibrosis.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Proteoglycans
/
Atrophy
/
Tissue Donors
/
Biopsy
/
Fibrosis
/
Biomarkers
/
Prospective Studies
/
Kidney Transplantation
/
Extracellular Matrix
/
Syndecan-4
Type of study:
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Annals of Surgical Treatment and Research
Year:
2019
Type:
Article
Similar
MEDLINE
...
LILACS
LIS